Patents by Inventor Martin TENNISWOOD

Martin TENNISWOOD has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230257826
    Abstract: The present invention relates to compositions and methods for diagnosing, prognosing, monitoring, and treating a patient with prostate cancer. In particular, the invention relates to the use of miRNA and snoRNA as expression signatures for identifying a clinically significant prostate cancer.
    Type: Application
    Filed: April 24, 2023
    Publication date: August 17, 2023
    Applicant: miR Scientific, LLC
    Inventors: Martin Tenniswood, Albert Gregory DiRienzo, Wei-Lin Winnie Wang
  • Patent number: 11661633
    Abstract: The present invention relates to compositions and methods for diagnosing, prognosing, monitoring, and treating a patient with prostate cancer. In particular, the invention relates to the use of miRNA and snoRNA as expression signatures for identifying a clinically significant prostate cancer.
    Type: Grant
    Filed: March 14, 2020
    Date of Patent: May 30, 2023
    Assignee: MIR SCIENTIFIC LLC
    Inventors: Martin Tenniswood, Albert Gregory DiRienzo, Wei-Lin Winnie Wang
  • Publication number: 20200291485
    Abstract: The present invention relates to compositions and methods for diagnosing, prognosing, monitoring, and treating a patient with prostate cancer. In particular, the invention relates to the use of miRNA and snoRNA as expression signatures for identifying a clinically significant prostate cancer.
    Type: Application
    Filed: March 14, 2020
    Publication date: September 17, 2020
    Applicant: miR Scientific, LLC
    Inventors: Martin Tenniswood, Albert Gregory DiRienzo, Wei-Lin Winnie Wang
  • Publication number: 20190144951
    Abstract: The present disclosure relates to compositions and methods for diagnosing, prognosing, monitoring, and treating a patient with prostate cancer. In particular, the disclosure relates to ncRNAs as diagnostic markers for determination of proper treatment administration.
    Type: Application
    Filed: June 8, 2017
    Publication date: May 16, 2019
    Applicants: miR Scientific, LLC, The Research Foundation for The State University of New York
    Inventors: Martin TENNISWOOD, Wei-Lin Winnie WANG, Gregory DIRIENZO, Tucker CONKLIN